MIRA
INFORM REPORT
|
Report Date : |
11.08.2012 |
IDENTIFICATION DETAILS
|
Name : |
QUALICAPS EUROPE SA |
|
|
|
|
Registered Office : |
Cl. La Granja, 49 Alcobendas, 28108 |
|
|
|
|
Country : |
Spain |
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Year of Establishment : |
1992 |
|
|
|
|
Com. Reg. No.: |
A80412836 |
|
|
|
|
Legal Form : |
Public Subsidiary |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical preparations |
|
|
|
|
No. of Employees : |
223 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Spain |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
QUALICAPS EUROPE SA
Cl. La Granja, 49
Alcobendas, 28108
Spain
Tel :+(34) 916630800
Fax :+(34) 916630830
Website: www.shionogi-qualicaps.com
Synthesis
|
Employees : 223 Company Type : Public Subsidiary Corporate Family : 27 Companies Ultimate Parent :Shionogi
& Co Ltd Incorporation Date : 1992 Auditor : Kpmg Auditores Sl Financials in :USD
(Millions) Fiscal Year End :25-Jan-2012 Reporting Currency :Euro Annual Sales :58.0 1 Net Income :8.8 Total Assets :72.2
|
Business Description
Supplier of two-piece capsules, equipment and technology: pharmaceutical capsules; health and nutrition capsules; manufacture of capsule filling and sealing equipment; manufacture of check-weighing and inspection machinery
|
|
|
|
|
Industry
|
Industry |
Biotechnology and Drugs |
|
ANZSIC 2006: |
1841 - Human Pharmaceutical and
Medicinal Product Manufacturing |
|
NACE 2002: |
2442 - Manufacture of
pharmaceutical preparations |
|
NAICS 2002: |
325412 - Pharmaceutical Preparation
Manufacturing |
|
UK SIC 2003: |
24421 - Manufacture of
medicaments |
|
US SIC 1987: |
2834 - Pharmaceutical
Preparations |
Key Executives
|
Name |
Title |
|
Carlos Martinez Sierra |
President, Member Of The Board |
|
Oscar Sanchez-Vilar Burdiel |
Non Consellor Secretary |
|
Enrique Requejo Gabas |
Quality Control Manager |
|
Juan Francisco Bermejo Bueno |
Joint Attorney |
|
Salvatore Sarno Michael |
Member Of The Board |
Registered No.(ESP): A80412836
1 - Profit & Loss
Item Exchange Rate: USD 1 = EUR 0.7209812
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.7689981
Location
Cl. La Granja, 49
Alcobendas, 28108
Spain
Tel :+( 34) 916630800
Fax :+( 34) 916630830
Sales EUR(mil): 41.8
Assets EUR(mil): 55.6
Employees: 223
Fiscal Year End: 25-Jan-2012
Industry: Biotechnology and Drugs
Incorporation Date: 1992
Company Type: Public Subsidiary
Quoted Status: Not Quoted
Previous Name: Shionogi Qualicaps SA
Registered No.(ESP): A80412836
President, Member Of The Board: Carlos
Martinez Sierra
|
ANZSIC 2006 Codes: |
||
|
2469 |
- |
Other Specialised Machinery and Equipment
Manufacturing |
|
1841 |
- |
Human Pharmaceutical and Medicinal Product
Manufacturing |
|
NACE 2002 Codes: |
||
|
2924 |
- |
Manufacture of other general purpose
machinery not elsewhere classified |
|
2442 |
- |
Manufacture of pharmaceutical preparations |
|
NAICS 2002 Codes: |
||
|
325412 |
- |
Pharmaceutical Preparation Manufacturing |
|
333298 |
- |
All Other Industrial Machinery
Manufacturing |
|
US SIC 1987: |
||
|
3559 |
- |
Special Industry Machinery, Not Elsewhere
Classified |
|
2834 |
- |
Pharmaceutical Preparations |
|
UK SIC 2003: |
||
|
24421 |
- |
Manufacture of medicaments |
|
2924 |
- |
Manufacture of other general purpose
machinery not elsewhere classified |
Manufacture of pharmaceutical preparations
More Business Descriptions
Supplier of two-piece capsules, equipment and technology: pharmaceutical
capsules; health and nutrition capsules; manufacture of capsule filling and
sealing equipment; manufacture of check-weighing and inspection machinery
Mfr. & Sales of Capsules
Financial
Data
|
|
||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||
Branch Offices
Location
Avda Icaria 150
Barcelona, 08005
Tel:+(34) 932255043
Key Corporate Relationships
|
|
|||||||||||
|
|
|
|
||||||||
|
Corporate Family |
Corporate Structure
News: |
|
|
|
|
Qualicaps Europe Sa |
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
|
Parent |
Osaka-Shi |
Japan |
Biotechnology and Drugs |
3,384.9 |
6,132 |
||
|
Acquisition of C & O Pharmaceutical Tech (Holdings)
Ltd proposed/announced.See corporate structure news on Shionogi & Co
Ltd for details |
|||||||
|
Subsidiary |
Florham Park, NJ |
United States |
Biotechnology and Drugs |
382.3 |
1,000 |
|
|
|
Subsidiary |
San Diego, CA |
United States |
Biotechnology and Drugs |
|
150 |
|
|
|
Subsidiary |
Westlake, TX |
United States |
Biotechnology and Drugs |
14.8 |
22 |
|
|
|
Branch |
Alpharetta, GA |
United States |
Biotechnology and Drugs |
15.2 |
16 |
|
|
|
Subsidiary |
Atlanta, GA |
United States |
Biotechnology and Drugs |
382.3 |
920 |
|
|
|
Facility |
Settsu, Osaka |
Japan |
Personal and Household Products |
|
500 |
|
|
|
Subsidiary |
Toyonaka, Osaka |
Japan |
Business Services |
|
360 |
|
|
|
Subsidiary |
Hong Kong |
Hong Kong |
Miscellaneous Financial Services |
83.9 |
244 |
|
|
|
Acquisition by Shionogi & Co., Ltd.
proposed/announced.See corporate structure news on Shionogi & Co
Ltd for details |
|||||||
|
Subsidiary |
Alcobendas, Madrid |
Spain |
Biotechnology and Drugs |
58.0 |
223 |
|
|
|
Branch |
Taipei |
Taiwan |
Biotechnology and Drugs |
1.0 |
150 |
|
|
|
Subsidiary |
Taipei |
Taiwan |
Biotechnology and Drugs |
1.0 |
120 |
|
|
|
Subsidiary |
Shiga |
Japan |
Biotechnology and Drugs |
|
100 |
|
|
|
Subsidiary |
Florham Park, NJ |
United States |
Biotechnology and Drugs |
|
75 |
|
|
|
Subsidiary |
Osaka |
Japan |
Biotechnology and Drugs |
1.0 |
30 |
|
|
|
Subsidiary |
Koka, Shiga |
Japan |
Biotechnology and Drugs |
|
20 |
|
|
|
Subsidiary |
Pine Brook, NJ |
United States |
Scientific and Technical Instruments |
|
11 |
|
|
|
Subsidiary |
Koka |
Japan |
Biotechnology and Drugs |
1.0 |
|
|
|
|
Subsidiary |
Osaka |
Japan |
Biotechnology and Drugs |
1.0 |
|
|
|
|
Subsidiary |
Osaka |
Japan |
Business Services |
|
|
|
|
|
Subsidiary |
Amagasaki, Hyogo |
Japan |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Toyonaka, Osaka |
Japan |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Amsterdam |
Netherlands |
Miscellaneous Financial Services |
|
|
|
|
|
Subsidiary |
Tokushima |
Japan |
Biotechnology and Drugs |
|
|
|
|
|
Facility |
Iwate |
Japan |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Tokushima |
Japan |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Osaka |
Japan |
Biotechnology and Drugs |
|
|
|
|
Executives Report
Board of Directors
|
|
|
|
|
|||
|
President, Member Of The Board |
Director/Board Member |
|||
|
Member Of The Board |
Director/Board Member |
|||
|
Member Of The Board |
Director/Board Member |
|||
|
Member Of The Board |
Director/Board Member |
|||
|
|
|
|
|
Executives |
|
|
|
|||
|
President, Member Of The Board |
President |
|||
|
Non Consellor Secretary |
Administration Executive |
|||
|
Joint Attorney |
Legal Executive |
|||
|
Joint Attorney |
Legal Executive |
|||
|
Quality Control Manager |
Quality Executive |
|||
|
Single Partner |
Partner |
Annual Profit & Loss
|
|
|
|
||||
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
|
|
Period
Length |
12
Months |
12
Months |
12
Months |
|
|
|
Filed
Currency |
EUR |
EUR |
EUR |
|
|
|
Exchange
Rate (Period Average) |
0.755078 |
0.719047 |
0.683679 |
|
|
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
|
|
|
|
Charges |
47.3 |
53.3 |
98.5 |
|
|
|
Stock Reduction |
- |
0.3 |
0.8 |
|
|
|
Supplies |
17.6 |
15.4 |
19.3 |
|
|
|
Consumption of Raw Materials |
17.6 |
15.4 |
19.3 |
|
|
|
Staff Costs |
14.1 |
16.8 |
16.4 |
|
|
|
Wages and Salaries |
10.7 |
12.4 |
12.3 |
|
|
|
Social Security Costs |
3.5 |
4.3 |
4.1 |
|
|
|
Depreciation |
3.0 |
3.1 |
2.9 |
|
|
|
Allowance for Trade Operations |
-0.1 |
0.2 |
-0.2 |
|
|
|
Stock Provision Variation |
-0.1 |
0.1 |
-0.2 |
|
|
|
Losses from Unrecovered
Receivables |
0.0 |
0.1 |
0.0 |
|
|
|
Other Operating Charges |
12.5 |
13.6 |
15.0 |
|
|
|
External Services |
12.2 |
13.4 |
14.8 |
|
|
|
Taxes |
0.2 |
0.3 |
0.2 |
|
|
|
Operating
Benefits |
8.5 |
7.9 |
12.6 |
|
|
|
Financials and Similar Charges |
0.1 |
0.2 |
0.1 |
|
|
|
Due to Liabilities With Group
Companies |
0.1 |
- |
0.1 |
|
|
|
Due to Other Liabilities |
0.0 |
0.2 |
- |
|
|
|
Changes in Financial
Investment Provisions |
- |
1.5 |
38.7 |
|
|
|
Net
Financial Income |
0.2 |
- |
- |
|
|
|
Profit
From Ordinary Activities |
8.7 |
6.7 |
- |
|
|
|
Losses From Assets and
Securities Portfolio |
0.0 |
0.0 |
- |
|
|
|
Extraordinary Expenses |
- |
0.1 |
- |
|
|
|
Extraordinary
Profit |
0.1 |
- |
1.1 |
|
|
|
Profit
Before Taxes |
8.7 |
6.6 |
- |
|
|
|
Corporation Tax |
0.3 |
2.0 |
5.4 |
|
|
|
Financial
Year Result (Profit) |
8.4 |
4.7 |
- |
|
|
|
Income |
55.8 |
57.9 |
75.2 |
|
|
|
Net Total Sales |
55.4 |
57.3 |
66.9 |
|
|
|
Sales |
55.4 |
57.3 |
66.9 |
|
|
|
Increase in Stocks |
0.1 |
- |
- |
|
|
|
Miscellaneous Operating Income |
0.0 |
0.0 |
0.0 |
|
|
|
Grants |
0.0 |
0.0 |
0.0 |
|
|
|
Income From Other Securities
and Receivables |
0.0 |
0.0 |
0.8 |
|
|
|
From Non-Group Companies |
0.0 |
0.0 |
0.8 |
|
|
|
Income From Miscellaneous
Interests |
0.2 |
0.5 |
1.9 |
|
|
|
From Group Companies |
0.1 |
0.5 |
1.4 |
|
|
|
Miscellaneous Interests |
0.0 |
0.0 |
0.5 |
|
|
|
Gains from Exchange Rate |
0.1 |
0.0 |
4.5 |
|
|
|
Negative
Financial Results |
- |
1.1 |
31.5 |
|
|
|
Ordinary
Activities' Losses |
- |
- |
18.9 |
|
|
|
Profit on Disposal of Assets |
- |
- |
0.0 |
|
|
|
Extraordinary Income |
0.1 |
- |
1.1 |
|
|
|
Negative
Extraordinary Results |
- |
0.1 |
- |
|
|
|
Losses
Before Taxes |
- |
- |
17.9 |
|
|
|
Financial
Year Result (Losses) |
- |
- |
23.3 |
|
|
Annual Balance Sheet
Financials
in: USD (mil)
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745406 |
0.696986 |
0.719399 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Software |
0.1 |
0.1 |
0.2 |
|
Total Intangible Fixed Assets |
0.1 |
0.1 |
0.2 |
|
Land and Construction |
12.1 |
13.5 |
13.4 |
|
Technical Installations and Machinery |
5.8 |
6.0 |
6.5 |
|
Other Installations, Tools, and Furniture |
3.6 |
3.7 |
4.0 |
|
Tangible Fixed Assets Under Construction |
5.7 |
1.8 |
1.0 |
|
Other Tangible Assets |
0.2 |
0.2 |
0.3 |
|
Total Tangible Fixed Assets |
27.4 |
25.3 |
25.2 |
|
Investments in Group Companies |
17.7 |
1.4 |
1.4 |
|
Other Receivables |
0.0 |
0.0 |
0.0 |
|
Long-Term Guarantees and Deposits |
0.0 |
0.0 |
0.0 |
|
Financial Investments |
17.7 |
1.5 |
1.4 |
|
Total Fixed Assets |
45.2 |
26.9 |
26.8 |
|
Raw Materials and Other Consumables |
3.6 |
3.6 |
3.6 |
|
Goods in Process |
0.1 |
0.2 |
0.1 |
|
Finished Products |
4.3 |
3.6 |
3.2 |
|
Total Stocks |
8.0 |
7.4 |
6.9 |
|
Trade Debtors |
9.3 |
9.2 |
11.1 |
|
Receivables, Group Companies |
0.2 |
0.1 |
0.3 |
|
Other Debtors |
0.1 |
0.1 |
0.1 |
|
Staff |
0.0 |
0.0 |
0.0 |
|
Public Bodies |
1.7 |
0.5 |
0.4 |
|
Total Debtors |
11.2 |
9.9 |
11.8 |
|
Receivables from Group Companies |
6.9 |
24.5 |
12.1 |
|
Short-Term Securities Portfolio |
- |
- |
6.0 |
|
Total Short-Term Investments |
6.9 |
24.5 |
18.1 |
|
Cash |
3.1 |
2.2 |
0.7 |
|
Prepayments and Accrued Income |
0.1 |
0.2 |
0.2 |
|
Total Current Assets |
29.4 |
44.2 |
37.7 |
|
Total Assets |
74.5 |
71.1 |
64.5 |
|
Revaluation Reserves |
1.5 |
1.3 |
2.6 |
|
Legal Reserve |
4.2 |
4.5 |
4.3 |
|
Miscellaneous Reserves |
21.8 |
18.8 |
39.0 |
|
Capital Adjustment to Euros |
0.0 |
0.0 |
0.0 |
|
Total Reserves |
26.0 |
23.3 |
43.3 |
|
Profit or Loss for the Financial Year |
8.6 |
4.8 |
-22.1 |
|
Total Equity |
57.0 |
51.8 |
45.5 |
|
Long-Term Liabilities from Capital Leases |
0.0 |
- |
- |
|
Total Amounts Owed to Credit Institutions |
0.0 |
- |
- |
|
Long-Term Payables to Public Bodies |
- |
0.1 |
0.2 |
|
Total Other Creditors |
- |
0.1 |
0.2 |
|
Total Long Term Liabilities |
0.0 |
0.1 |
0.2 |
|
Short-Term Liabilities from Capital Leases |
0.0 |
- |
- |
|
Total Amounts Owed to Credit Institutions |
0.0 |
- |
- |
|
Amounts Owed to Group Companies |
8.1 |
11.7 |
7.4 |
|
Total Short-Term Amounts Owed to Group and
Associa |
8.1 |
11.7 |
7.4 |
|
Advanced Payments from Customers |
- |
0.1 |
0.1 |
|
Amounts Owed for Purchases of Goods or
Services |
7.5 |
5.4 |
8.4 |
|
Total Trade Creditors |
7.5 |
5.5 |
8.4 |
|
Public Bodies |
0.6 |
1.2 |
2.2 |
|
Miscellaneous Debts |
0.3 |
0.1 |
0.1 |
|
Wages and Salaries Payable |
1.0 |
0.7 |
0.8 |
|
Total Other Creditors |
1.9 |
2.0 |
3.1 |
|
Total Short Term Creditors |
17.6 |
19.2 |
18.9 |
|
Total
Liabilities and Equity |
74.5 |
71.1 |
64.5 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.34 |
|
|
1 |
Rs.86.45 |
|
Euro |
1 |
Rs.68.04 |
INFORMATION DETAILS
|
Report Prepared by
: |
NLM |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.